Wugen
Wugen: Advancing immuno-oncology with enhanced, donor-derived cell therapies for various cancers.
Founded
2018Wugen: Advancing immuno-oncology with enhanced, donor-derived cell therapies for various cancers.
Wugen, founded with a mission to advance immuno-oncology, is a clinical-stage company specializing in developing off-the-shelf cellular therapies for cancer. The company's core vision is to harness the power of natural killer (NK) cells and chimeric antigen receptor T (CAR-T) cells to create effective treatments for solid tumors, acute myeloid leukemia (AML), and T-cell malignancies. By using enhanced, donor-derived cell therapies, Wugen aims to provide innovative solutions that address significant unmet needs in cancer treatment.
Notable figures affiliated with Wugen include its leadership team and a distinguished Scientific Advisory Board composed of experts in oncology and cell therapy. The company has garnered support from prominent investors committed to advancing cancer therapeutics. Key achievements include the development of their proprietary Memory NK and CAR-T platforms, which have shown promising preclinical results. Wugen's impact lies in its potential to revolutionize cancer treatment through cutting-edge immuno-oncology therapies, offering new hope to patients with challenging malignancies.
Companies similar to Wugen include Catamaran Bio, Modulus Therapeutics, Artiva Biotherapeutics and Windmil Therapeutics.
Wugen was founded in 2018.
Wugen's headquarters is located in St. Louis, MO, US.
Wugen's most recent funding round was for $172M (USD) in July 2021.
As of Jul 15, 2021, Wugen has disclosed funding of $172M (USD). Undisclosed round amounts are excluded.
Wugen has 89 employees as of Feb 5, 2024.
Windmil Therapeutics
